Fig. 27.1 Tonometry measurement (illustration of the tonometer in use) Two independent assessors measured all patients using the agreed standardised protocol. Nodules to be assessed were identified and agreed by…
Examples of molecules previously identified in the Dupuytren Disease extracellular matrix Structural and nonstructural ECM molecules Matricellular (nonstructural) ECM molecules Growth and differentiation factors Collagens (I, III, + many others)…
Fig. 25.1 Severe contracture of the two ulnar rays 25.3 Treating a Severe PIP Contracture Several problems need to be addressed when treating a severe PIPj contracture. 25.3.1 Skin After…
© Springer International Publishing Switzerland 2017Paul M. N. Werker, Joseph Dias, Charles Eaton, Bert Reichert and Wolfgang Wach (eds.)Dupuytren Disease and Related Diseases – The Cutting Edge10.1007/978-3-319-32199-8_57 57. International Clinical Research – The Australian Perspective: A Personal View…
© Springer International Publishing Switzerland 2017Paul M. N. Werker, Joseph Dias, Charles Eaton, Bert Reichert and Wolfgang Wach (eds.)Dupuytren Disease and Related Diseases – The Cutting Edge10.1007/978-3-319-32199-8_55 55. Patient-Rated Outcome Measures and Dupuytren Contracture Joseph J. Dias1 (1) University Hospitals…
© Springer International Publishing Switzerland 2017Paul M. N. Werker, Joseph Dias, Charles Eaton, Bert Reichert and Wolfgang Wach (eds.)Dupuytren Disease and Related Diseases – The Cutting Edge10.1007/978-3-319-32199-8_54 54. Clinical Research: International Collaboration to Execute High-Powered Clinical Trials Marie A. Badalamente1 …
© Springer International Publishing Switzerland 2017Paul M. N. Werker, Joseph Dias, Charles Eaton, Bert Reichert and Wolfgang Wach (eds.)Dupuytren Disease and Related Diseases – The Cutting Edge10.1007/978-3-319-32199-8_53 53. How Should We Fund Basic Research of Dupuytren Disease? Dominic Furniss1 …
© Springer International Publishing Switzerland 2017Paul M. N. Werker, Joseph Dias, Charles Eaton, Bert Reichert and Wolfgang Wach (eds.)Dupuytren Disease and Related Diseases – The Cutting Edge10.1007/978-3-319-32199-8_52 52. The Future of Basic Dupuytren Disease Research David B. O’Gorman1 (1) Departments…
Fig. 45.1 Model of target cells and involved factors. Advanced model of target cells and factors involved in the therapeutic modulation of hyperproliferative/fibrotic benign diseases by a low-dose radiation therapy….
Fig. 13.1 Overview network analysis. Simplified workflow of the network analysis integrating GWAS and transcriptome data to search for disease-specific sub-networks in DD. In the first step SNP-based p-values are…
